title: Extravasation of pegylated-liposomal doxorubicin: favorable outcome after immediate subcutaneous administration of corticosteroids.
abstract: A massive extravasation of pegylated-liposomal doxorubicin (Doxil) accidentally occurred, affecting the right forearm of a 54-year-old woman with metastatic ovarian cancer who was receiving an intravenous infusion of the drug. In accordance with the institutional guidelines for vesicant drugs, a corticosteroid preparation was immediately injected subcutaneously into the surrounding tissues. Clobetasol propionate and an ice pack were then topically applied to the affected region. There were no serious complications at the extravasation site, such as tissue necrosis or severe pain, and only a transient erythema of the skin and desquamation remained after 2 months.
authors.affiliation: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. ayakom@med.nagoya-u.ac.jp
authors.forename: Ayako
authors.initials: A
authors.lastname: Mitsuma
authors.forename: Masataka
authors.initials: M
authors.lastname: Sawaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Shibata
authors.forename: Sachi
authors.initials: S
authors.lastname: Morita
authors.forename: Megumi
authors.initials: M
authors.lastname: Inada
authors.forename: Tomoya
authors.initials: T
authors.lastname: Shimokata
authors.forename: Mihoko
authors.initials: M
authors.lastname: Sugishita
authors.forename: Koichi
authors.initials: K
authors.lastname: Kitagawa
authors.forename: Masaki
authors.initials: M
authors.lastname: Sawada
authors.forename: Akihiro
authors.initials: A
authors.lastname: Nawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ando
mesh_terms: D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002990:Clobetasol / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004487:Edema / Q000188:drug therapy / Q000209:etiology; D004890:Erythema / Q000188:drug therapy / Q000209:etiology; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005542:Forearm / Q000098:blood supply*; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007036:Hypothermia, Induced; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000903:Antibiotics, Antineoplastic; D005938:Glucocorticoids; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D002990:Clobetasol